Literature DB >> 17971818

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

A Gaedigk1, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder.   

Abstract

Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the growing number of alleles and their range of activity. This complexity poses a challenge in translational research where genotyping is being considered as a tool to personalize drug therapy. To simplify genotype interpretation and improve phenotype prediction, we evaluated the utility of an "activity score" (AS) system. Over 25 CYP2D6 allelic variants were genotyped in 672 subjects of primarily Caucasian and African-American heritage. The ability of genotype and AS to accurately predict phenotype using the CYP2D6 probe substrate dextromethorphan was evaluated using linear regression and clustering methods. Phenotype prediction, given as a probability for each AS group, was most accurate if ethnicity was considered; among subjects with genotypes containing a CYP2D6*2 allele, CYP2D6 activity was significantly slower in African Americans compared to Caucasians. The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971818     DOI: 10.1038/sj.clpt.6100406

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  259 in total

1.  BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Authors:  Caterina Chianella; Daniela Gragnaniello; Pierpaolo Maisano Delser; Maria Francesca Visentini; Elisabetta Sette; Maria Rosaria Tola; Guido Barbujani; Silvia Fuselli
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

2.  Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.

Authors:  Andrea Gaedigk; Maria Isidoro-García; Robin E Pearce; Santiago Sánchez; Virginia García-Solaesa; Carolina Lorenzo-Romo; Gloria Gonzalez-Tejera; Susan Corey
Journal:  Eur J Clin Pharmacol       Date:  2010-05-16       Impact factor: 2.953

3.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Authors:  Xia Yang; Bin Zhang; Cliona Molony; Eugene Chudin; Ke Hao; Jun Zhu; Andrea Gaedigk; Christine Suver; Hua Zhong; J Steven Leeder; F Peter Guengerich; Stephen C Strom; Erin Schuetz; Thomas H Rushmore; Roger G Ulrich; J Greg Slatter; Eric E Schadt; Andrew Kasarskis; Pek Yee Lum
Journal:  Genome Res       Date:  2010-06-10       Impact factor: 9.043

4.  Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Authors:  T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 5.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 6.  [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Authors:  J C Stingl; K S Just; K Kaumanns; M Schurig-Urbaniak; C Scholl; D von Mallek; J Brockmöller
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

7.  Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Authors:  Weize Huang; Mariko Nakano; Jennifer Sager; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-08-31       Impact factor: 3.922

8.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

Review 9.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

10.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.

Authors:  Vural Ozdemir; Guilherme Suarez-Kurtz; Raphaëlle Stenne; Andrew A Somogyi; Toshiyuki Someya; S Oğuz Kayaalp; Eugene Kolker
Journal:  OMICS       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.